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 Abstract: 
Once injected into a living organism, cells diffuse or migrate around the initial injection point 
and become impossible to be visualized and tracked in vivo. The present work concerns the 
development of a new technique for therapeutic cell labelling and subsequent in vivo 
visualisation and magnetic retention. We hypothesized and subsequently demonstrated that 
nanohybrids made of persistent luminescence nanoparticles (PLNPs) and ultrasmall 
superparamagnetic iron oxide nanoparticles (USPIOs) incorporated into a silica matrix can be 
used as an effective nanoplatform to label therapeutic cells in a non-toxic way in order to 
dynamically track them in real-time in vitro and in living mouse. As a proof-of-concept, we 
have shown that once injected, these labelled cells could be visualized and attracted in vivo 
using a magnet. This first step suggests that our nanohybrids represent efficient 
multifunctional nanoprobes for further imaging guided cell therapies development. 
 
1) Introduction 
In recent years, cells have shown great potential in a number of biomedical applications and 
researches in this area received much attention.
[1]
 Cell therapies using mesenchymal stem 
cells (MSC) or endothelial progenitor cells (EPC) have demonstrated significant potential for 
the treatment and cure of several diseases such as cancer, diabetes, neurodegenerative or 
cardiovascular diseases
[2-4]
 and also for regeneration in peripheral arterial disease (PAD) in 
both animal and human studies.
[5-6]
 
Most current preclinical and clinical cell therapy trials consist of local or systemic delivery of 
stem or progenitor cells, and rely on the migration and retention of implanted cells at sites of 
injury.
[7]
 However, determining the fate and localization of these cells inside the body, as well 
as targeting the cells to a particular location, are still major challenges. To address these 
concerns, several methods have been developed to label therapeutic cells ex vivo in order to 
monitor their fate after in vivo administration. Among the different available modalities, X-
ray computed tomography (CT),
[8] 
magnetic resonance imaging (MRI),
[9] 
positron emission 
tomography (PET)
[10]
 and single photon emission computed tomography (SPECT)
[11]
 have 
been used. However, the detection sensitivity of transplanted cells using such techniques is in 
some cases very low, or rendered difficult and costly by the use of radiopharmaceutical 
compounds. Optical imaging is expected to contribute to the development of cell 
transplantation, as it is less costly, easier to handle, non-ionizing and very sensitive.
[12] 
For 
that purpose, various optical labelling techniques have been developed to apprehend cell 
behavior in vitro and in vivo.
[13] 
However, optical in vivo detection is impaired by the 
autofluorescence signal coming from the body when exciting the probes.
[14]
 To overcome this 
parasitic signal, our group pioneered the use of persistent luminescent nanoparticles (PLNPs) 
for in vivo imaging.
 
Acting as optical capacitors, PLNPs can emit light in the tissue 
transparency window for minutes to hours after the end of an UV or visible illumination, 
leading to signals without autofluorescence and high target to background ratio.
[15-20]
 
Recently, ultrasensitive detection of labelled cells in small animals either after intravenous 
(IV) or subcutaneous (SC) injection was demonstrated in preliminary studies using 
PLNPs.
[18,21-22]
  
The long-term efficacy of stem cells therapy is presently relatively low, which can be due to a 
lack of cell retention in the treatment area,
[23]
 misplaced-injection, or cell injection into highly 
fibrotic tissues.
[24]
 Fortunately, unproperly localized injection can be prevented by real-time 
imaging guidance to ensure sufficient cell delivery to the desired tissue location. In order to 
improve cell delivery, several reports have shown that the in vivo biodistribution of cells 
labelled with magnetic nanoparticles could be influenced by applying a magnetic field and 
gradient.
[25-26]
 Various preclinical studies have exploited the magnetic properties acquired by 
cells carrying magnetic nanoparticles in order to increase the retention of implanted cells at 
specific sites within the body, for example with endothelial cells or EPC.
[27-30]
 
Recently, we have developed a modified approach to synthesize a new class of mesoporous 
nanohybrids (MPNHs) consisting of PLNPs and USPIOs incorporated into the same 
mesoporous silica matrix.
[31]
 We thus wondered whether these new nanohybrids could be used 
to label cells of interest in order to both control their in vivo fate, using their magnetic 
property, and to follow in real-time their distribution, using their persistent luminescent 
property, after injection. As a model, we chose a subpopulation of EPC called “late” EPC or 
endothelial colony-forming cells (ECFC) that present blood vessel-forming ability.
[32-33]
 
Herein, we report the use of MPNHs to label ECFC in non-toxic conditions, allowing these 
cells to keep their proliferation ability and biological properties. After labelling, it was 
possible to detect the cells in vivo and we show that MPNHs-COOH labelled ECFC can be 
remotely controlled in vivo by applying an external magnetic field and gradient. 
 
2. Results and discussion 
2.1. Characterization and functionalization of the nanohybrids 
We have previously reported the synthesis of different mesoporous nanohybrids (MPNH) 
made of PLNPs and containing increasing amount of USPIOs (0, 1.4, 3.5 and 5.2% (w/w), 
named MPNH0, MPNH1, MPNH2 and MPNH3, respectively) incorporated into a silica matrix 
(Fig 1.a-d). These nanohybrids have been synthesized using tetraethoxysilane (TEOS), 
cetyltrimethylammonium bromide (CTAB) and comprise the two types of nanoparticles 
(PLNPs and USPIOs).
[31]
 In order to evaluate the influence of the nanohybrids surface both on 
the internalization efficacy and on the cell cytotoxicity, these nanohybrids have been coated 
either with (3-aminopropyl)triethoxysilane (APTES) to introduce amine groups on the 
MPNHs (MPNH-NH2) or with diglycolic anhydride (DGA) to introduce carboxylic acids 
functions (MPNH-COOH) (Fig 1.f). The different MPNHs have a spherical-like shape (Fig 
1.a-d) and persistent luminescence properties after both UV and visible excitation (Fig 1.e). 
The light emission can persist for several dozen of minutes after the end of the excitation, 
which is necessary to get in vivo optical signals without background. Figure 1.e also informs 
about the compared efficacy of UV versus visible illumination. As shown on the 
corresponding decay curves, the persistent luminescence signal is approximately one log 
weaker following visible light excitation, in comparison with the signal obtained following 
UV excitation. Such typical trend regarding the persistent luminescence signal of these 
MPNHs matches the results demonstrated earlier in several other studies from our group.
[31,34] 
More importantly, the persistent luminescence properties of MPNHs do not vary with the 
percentage of USPIO (Fig 1.e). As expected, the functionalization procedure has an effect on 
the zeta potential of the MPNHs: MPNHs-NH2, with the amino groups, are protonated in mQ 
water and have positive surface charges, whereas MPNHs-COOH, with the carboxylic acids, 
have negative zeta potentials (Table 1). In addition, the amount of USPIOs does not seem to 
have any major impact on the global physicochemical properties of the MPNHs. Notably, all 
MPNHs display both similar zeta potential, either positive around + 40 mV with MPNHs-NH2 
or negative around – 40 mV with MPNHs-COOH, and hydrodynamic diameters which are 
rather stable around 190 nm from MPNH0-COOH to MPNH3-COOH. 
 
2.2. In vitro cell labelling and toxicity assays 
As a cell model we have chosen ECFC, a variety of endothelial progenitors.
[32,33]
 Thus, our 
objective was to find non-toxic conditions to label ECFC with MPNH and allow in vivo cell 
tracking under magnetic control. 
We first assessed the influence of three parameters designated as the type of MPNH, the 
surface coating (-NH2 or -COOH) and the incubation time (6 h and 24 h) on the global ECFCs 
viability. To this end, 10
4
 cells deposited in 96-well plates were incubated with increasing 
amounts of nanoparticles. The Alamar blue test was used to evaluate the cell metabolic 
activity. As can be observed in Fig 2, the coating has an influence on cell viability. When we 
look at MPNH0 (nanohybrids with 0% of USPIOs), we can verify that amine-coated MPNHs 
are more cytotoxic than the carboxylic coated ones (Fig 2.a). This is certainly due to the 
positive charge of amine-coated MPNHs, leading to a higher cellular uptake as can be seen in 
the literature.
[35,36]
 This apparent toxicity is even more important when the incubation time 
increases from 6 to 24 hours. In contrast to particle coating, the amount of USPIOs in MPNH 
type (MPNH1-3) has little influence on the cell viability (Fig 2.a-d). Such absence of effect 
could be attributed to the fact that USPIOs are incorporated into the core of the silica matrix, 
therefore not in direct contact with the cells. Moreover, this trend is also in line with previous 
work in which USPIOs alone are not responsible for any significant cytotoxic effect at these 
concentrations (< 1mM) on endothelial cells.
[37,38]
 Finally, we observed that the low 
cytotoxicity of MPNHs-COOH is time independent. 
Beside the assessment of cellular metabolic activity by Alamar blue test, a cell proliferation 
assay was carried out up to 7 days post-labeling. For this purpose, we selected a concentration 
of MPNHs for which the cell viability with the Alamar blue test was above 80% at 24 h, i.e. 
0.25 mg.mL
-1
 (which correspond to 73,5 μg of MPNH per cm2). As can be seen from Fig 2.e, 
exposure of ECFC to MPNH3-NH2 appears to significantly alter the proliferation, as 
compared to a control group (CT). These results are consistent with our previous observation 
using the Alamar blue test. On the other hand, incubation of ECFC with MPNH3-COOH does 
not alter the proliferation of ECFC even after 7 days of proliferation (Fig 2.e). 
 
2.3. Cellular uptake of nanohybrids and opto-magnetic properties of labelled cells 
To determine the cell uptake of the MPNHs, different techniques have been used. Since the 
MPNHs-COOH are less cytotoxic, a concentration of 73,5 μg.cm-2 (0.25 mg/mL) for each 
MPNH-COOH was chosen for subsequent experiments. Transmission electron microscopy 
(TEM) observations of ECFC (6 h after labelling) principally show intra-endosomal 
confinement of the different MPNH1-3-COOH (Fig. 3.a-c), thus indicating that the low 
toxicity obtained by Alamar blue and proliferation tests are not the consequence of an absence 
of MPNHs-COOH internalization. We can also observe that these nanoparticles are 
internalized in different ways: some MPNHs are observed in small intracellular vesicles, 
while the majority are clustered in large lysosome-like vesicles. MPNHs isolated in small 
vesicles probably follow clathrin-dependent endocytosis, as previously shown with silica 
nanoparticles of about one hundred nanometers.
[39] 
In order to quantify the amount of MPNHs internalized by the cells, a magnetophoresis 
experiment was performed with cells labelled under conditions identical to that of the TEM 
experiment. By exploiting the magnetophoretic mobility of each labelled cell in suspension in 
a magnetic field gradient, we were able to determine the mass of iron per cell, deduced from 
the measurements of single cell velocity towards the magnet and cell radius (Fig 3.d).
[40]
 
Depending on the initial amount of USPIOs in MPNHs, the average mass of iron per cell 
approximately varies from 1.7 pg to 3 pg. These results are consistent with previous studies 
reporting EPC labelling with similar USPIOs, which obtained iron load from 3
[27] 
to 10
[37]
 pg 
per cell after incubation with iron concentrations of 0.1 or 5 mM. In our case, we used lower 
iron concentrations ranging from 0.043 to 0.16 mM (for 0.25 mg.mL
-1
 of MPNH1 and 
MPNH3, respectively) and USPIO were embedded in the silica matrix. In addition to the mean 
cellular magnetic load, this assay allows determining the iron mass distribution in the cell 
population (Figure S1). As MPNHs compositions were previously determined using ICP-
MS,
[31]
 we could determine the average mass of MPNHs per cell from the magnetophoresis 
data (Fig 3.e). Unexpectedly, the data from Figure 3.e indicate that the final amount of 
MPNHs per cell depends on the type of MPNHs. Indeed, the higher the USPIOs load in 
MPNHs, the lower the MPNHs uptake within each cell. Cells labelled with MPNH2-COOH 
contain the same amount of iron as those labelled with MPNH3-COOH (Fig 3.d). Thus, 
MPNH3 are less internalized than MPNH2 and MPNH1. 
After the magnetophoresis experiments, the cells were embedded in an agarose gel (1.5.10
6
 
cells per mL) to be characterized by MRI spectrometry in order to measure both T1 and T2 
relaxation times (Fig S.2 and 3.f). The presence of USPIOs in cells shows a slight but non-
significant influence on T1-weighted images, and no difference between the T1 of the gel 
containing the non-magnetic MPNH0-COOH labelled ECFC when compared to the control 
(Fig S2). As expected from magnetically labelled cells, the contrast evolution is much more 
important when looking at T2-weighted images.
[41]
 The gel containing the non-magnetic 
MPNH0-COOH labelled cells (dark blue column) displayed a contrast similar to the control 
gel containing unlabelled ECFC (light blue column), but the gels containing cells labelled 
with magnetic MPNH1,2,3 have a much lower T2 than the control (Fig 3.f). 
Due to the dual imaging properties of PLNPs, the labelled cells can be readily detected 
through their luminescence emission. We compared the luminescence intensity of cells 
labelled with the four MPNHs under the same conditions. The gels previously used for the 
MRI experiment were illuminated with a visible LED and the persistent luminescence was 
measured (Fig 3.g). After visible illumination, the luminescence of the labelled cells clearly 
depends on the type of MPNH used. The more USPIO concentration in MPNHs, the lower is 
the cell luminescence. These variations in the luminescence emission are well correlated to 
the different cellular uptake reported before (Fig. 3.e). While MPNH3-COOH labelled cell 
have similar iron content and magnetophoretic mobility compared to MPNH2-COOH labelled 
cell, their luminescence is 6 times lower than those labelled with MPNH2-COOH (Fig 3.g) 
which is in line with the different cell uptake. In addition, despite the higher luminescence 
intensity of MPNH1-COOH labelled cells, their magnetic resonance detectability and 
magnetic attraction are very low compared to MPNH2-COOH labelled cells. Therefore, in a 
trade-off between cellular uptake, luminescence detection, MR detection and magnetophoretic 
mobility of cells, MPNH2-COOH appears as the best candidate to carry out further in vivo 
dual image-guided and magnetically targeted cellular vectorization experiment. 
 
2.4 Functional properties of labelled cells 
For in vivo cell-based therapy, labelled progenitor cells should maintain crucial biological 
properties such as migration and capillary network formation abilities.
[38,42-44]
 Thus, we 
performed two sets of experiments to evaluate these properties. In vitro, the study of cell 
migration was carried out using a scratch/wound healing assay.
[45]
 We created a wound gap in 
a MPNH-labelled ECFC monolayer by scratching and monitored their migration towards the 
gap. The remaining gaps in MPNH treated wells were measured when control scratches had 
disappeared, around 24 h after their realization. Thus, injured areas were photographed to 
assess healing in each area. Fig 4.a shows the initial injuries (t0) and 24 hours later (24 h). The 
wounds are almost all closed after 24 h. Compared to the untreated control, only cells treated 
with MPNH1-COOH showed significant decrease in the cell ability to close up the gap (Fig 
4.f and 4.k). However, according to magnetophoresis results, MPNH1-COOH are the most 
internalized nanoparticles by ECFC among USPIOs containing MPNH. It is then conceivable 
that the greater internalization of MPNH1-COOH is responsible for the longer gap closing 
delay. It is worthwhile to precise that these results were obtained when cells were cultured in 
EGM-2 culture medium with 2 % (v/v) of foetal calf serum. This is necessary to avoid a bias 
due to cell proliferation: a control with 10 % (v/v) of foetal calf serum showed no difference 
in the wound healing between control and labelled ECFC (data not shown). 
As previously mentioned, ECFC have been shown to possess all the characteristics of 
endothelial progenitor to promote vascular repair and angiogenesis in vivo.
[32,33]
 Evaluating 
their ability to form vascular structures is one of the most specific ways to assess their ability 
to stimulate angiogenesis. This was tested in vitro by plating cells on constituents mimicking 
the extracellular matrix called Matrigel. Matrigel stimulates the organization of endothelial 
cells in networks evoking microvasculature. ECFC were labelled with MPNHs-COOH before 
seeding on Matrigel for 16 h. Under these experimental conditions, labelled and control ECFC 
formed extensive tubular network and the labelling process did not affect their properties (Fig 
5 and Fig S3). Typical characterizations of tubular structures include the total number of tubes 
and their mean lengths (Fig 5.f and 5.g, respectively), but it is also possible to evaluate the 
mean covered area, the number of loops, the total length of the network, the loops mean areas 
and perimeters, as well as the total branching points (Fig S3.a-f, respectively). As can be seen 
on the Fig 5 and Fig S3, there is no significant difference between the networks formed by 
labelled and non-labelled ECFC, regardless of the property under consideration. Similar 
results have already been reported in the literature using magnetic nanoparticles.
[37]
 
Altogether, these results confirm the MPNHs innocuousness regarding ECFC pro-
angiogenesis properties. 
 
2.5 Real time dynamic tracking and magnetic manipulation of transplanted cells in vivo 
As a proof of concept, we carried out in vivo experiment to determine whether it was possible 
to follow the distribution of MPNH-labelled ECFC in real time by luminescence imaging and 
simultaneously to control their localization by magnetic fields. ECFC were labelled with 
MPNH0-COOH or MPNH2-COOH under the same conditions to those previously used. 5.10
5
 
labelled ECFC were pre-illuminated by an orange LED for 5 min and were then injected in 
the peritoneal cavity of BALB/c mice. A luminescence image was acquired before and after 
applying a magnet to the right side of each mouse. The ECFC labelled with MPNH0-COOH 
represent the control group since MPNH0 do not contain USPIOs and therefore do not react to 
the presence of a magnetic field gradient. To evaluate the influence of the presence of an 
external magnet on the distribution of ECFC, we monitored the persistent luminescence 
intensity for twelve minutes throughout five regions of interest along the abdominal cavity 
(red rectangles, Fig 6.a). When looking at the signal of ECFC labelled with MPNH0-COOH, it 
can be seen that the luminescence in the mice does not evolve (Fig 6.b) and that the 
luminescence profile traced as indicated above is stable after applying the magnet against the 
right flank of the mouse (Fig 6.d). On the contrary, when looking at the signal of MPNH2-
COOH labelled ECFC, we observe a significant preferential accumulation with time of the 
luminescence situated in the right part of the abdomen towards the right flank of the mouse, 
where the magnet is placed (Fig 6.c). Moreover, the luminescence coming from the left half 
side of the mice did not change over time, unlike that of the right side. The persistent 
luminescence signal increases significantly in the closest area to the magnet (Fig 6.e). This 
graph confirms results from the luminescence images: the signal does not evolve at a distance 
greater than 2 cm from the magnet. This makes it possible to determine an effective distance 
of action of the magnet on the MPNH2-COOH labelled ECFC. Furthermore, the most 
important evolution of the luminescence takes place during the 3 or 4 first minutes of the 
experiment, suggesting that once cell sedimentation or tissue adhesion happen, no more cell 
movement can occur in our experimental conditions. 
These first experiments of magnetic cellular vectorization using MPNHs in vivo show the 
possibility to magnetically attract MPNHs-loaded cells injected into the peritoneal cavity and 
to optically localize them in real-time by luminescence measurements. This study proved, for 
the first time, the feasibility of using nanoparticles as a tool to magnetically vectorize and 
concomitantly track cell migration in vivo in real-time, without unnecessary sacrifice of the 
animal. The non-invasive nature of this technique opens access to information regarding cell 
magnetic vectorization dynamics in living animals. This proof of concept was made possible 
in our situation because it was realised on mice. As near-infrared luminescence does not have 
an important penetration depth, its actual potential would be limited to preclinical studies on 
small animals, per-operative imaging and surface applications (dermatology, gastro-intestinal 
endoscopy). Another promising enhancement of this technique could be achieved using PLNP 
emitting in the second near-infrared window (between 1.0 and 1.4 μm), as penetration depth is 
higher for this wavelength range. 
 
3. Conclusion 
Nanoparticles with persistent luminescence and magnetic properties were integrated into 
nanohybrids in order to label cells of therapeutic interest. In this study, we showed that with 
such MPNHs, it is possible to define non-toxic labelling conditions, which allow cells 
tracking in real-time using persistent luminescence. Moreover, this led to signals devoid of 
autofluorescence and allowed following the injected cells in vivo dynamic and attraction with 
a magnet. Our findings provide a proof-of-concept demonstrating that it is possible to realize 
real-time optical monitoring of magnetically targeted ECFC in vitro and in vivo with a good 
sensitivity using persistent luminescence. Thus, we postulate that, by applying an appropriate 
magnetic field gradient, the approach developed in this study could be useful to assess cell 
targeting to specific locations inside the body for cell-based therapies. This study also 
suggests the possibility to realize cell retention in the peritoneal cavity using our 
nanoparticles, which may be interesting for applications such as cancer cell therapies
[46]
 if 
similar results are further obtained with different kind of therapeutic cells. 
 
4. Experimental section 
Chemicals and biologics: 
Zinc nitrate hexahydrate (>99%), diglycolic anhydride (>90%) and dimethylhydroxylamine 
solution (40%) were obtained from Fluka. Gallium oxide (99.999%), chromium (III) nitrate 
nonahydrate (99.99%) and sodium n-dodecyl sulfate (99%) were purchased from Alfa Aesar. 
Dimethylformamide (>99.99%) was purchased from SDS. Cetyltrimethylammonium bromide 
(CTAB, >98%), tetraethyl orthosilicate (TEOS, >98%), iron (II) chloride tetrahydrate, caffeic 
acid and HCl were purchased from Sigma-Aldrich. Water was purified with a Millipore 
system (resistivity 18.2 MΩ cm). HBSS and D-PBS were purchased from Dubco. 
ECFC isolation, culture and labelling: 
Umbilical cord blood collected from consenting mothers was diluted in an equal volume of 
HBSS, and mononuclear cells were isolated by density-gradient centrifugation using 
1.077g.mL
-1
 Histopaque solution (Sigma Chemicals, Saint Quentin Fallavier, France) as 
described by Bompais et al.
[47]
 CD34+ cells were selected with immunomagnetic beads and 
the MACS technique (Miltenyi Biotec, Paris, France). They were plated on 0.2% gelatin-
coated 24-well plastic culture dishes at a density of 5.10
5
 cells/well in endothelial growth 
medium (EGM-2, Lonza, Walkersville, MD, USA). After 4 days, non-adherent cells were 
removed by thorough washing with culture medium. After 10 days of culture, ECFC colonies 
became visible microscopically. Cells were then detached with trypsin-EDTA (Eurobio, Les 
Ulis, France) and expanded in EGM-@ on 0.2% gelatin coated plates and grown at 37°C in a 
humidified 5% CO2 atmosphere for further use. ECFC were used 25 to 45 days after cord 
blood processing. 
Cell labelling was performed by adding a suspension of MPNHs in EGM-2 culture medium to 
adherent cells. Cells were incubated at 37°C for different incubation times (6 or 24h) with 
various MPNH concentrations. Incubation was followed by two washes with MPNH-free D-
PBS. 
Synthesis and functionalization of the four nanohybrids: 
Persistent luminescence nanoparticles (ZnGa2O4:Cr
3+
), maghemite ultrasmall iron oxide 
nanoparticles (γ-Fe2O3) and the four types of mesoporous nanohybrides were synthesized as 
previously described.
[31]
 
The surface functionalization of MPNHs was realized as follow: MPNH0,1,2,3-NH2 
nanoparticles were obtained by adding APTES (40 μL) to a suspension of MPNH0,1,2,3-OH (10 
mg) in DMF (4 mL). The reaction mixture was sonicated for the first 2 minutes using a 
Branson Ultrasonic Cleaner 1210 and kept under vigorous stirring for 5 hours at RT. 
Particles were washed from the unreacted APTES by three centrifugation/redispersion steps 
in DMF. MPNH0,1,2,3-COOH were obtained by having DGA (2.7 mg) react with MPNH0,1,2,3-
NH2 particles (10 mg) in DMF (4 mL) under vigorous stirring overnight at RT. After washing, 
MPNH0,1,2,3-COOH were dispersed in sterile glucose (5%). 
Alamar blue assay: 
Before realizing this assay, it is necessary to determine the linearity range of this test. 
Growing amounts of cells (nine conditions from 4.10
3
 to 2.10
4
 cells per well) were seeded in 
96-well flat bottom plates (Falcon, Strasbourg, France) and incubated subsequently in 
complete culture medium, without Alamar Blue reagent for 24 hours and with Alamar Blue 
for 5 hours. Fluorescence measurements were then realized every hour (λexc = 530 nm / λem = 
590 nm) with a Tecan Infinite Pro 2000 (Tecan Trading AG, Switzerland). This experiment 
allowed us to determine efficient conditions for the following cytotoxicity assays. 
ECFC were seeded at a density of 10
4
 cells per well in 96-well flat-bottom plates and 
incubated in complete culture medium (EGM-2) for 24 hours. Then, medium was replaced by 
EGM-2 containing increasing concentrations of MPNH-NH2 or MPNH-COOH. After 6 or 24 
hours, medium was removed and EGM-2 with Alamar Blue reagent (10%, v/v) was added for 
4 hours at 37°C. Cell viability is calculated from the measured fluorescence of metabolized 
Alamar Blue using a Tecan Infinite Pro 2000. 
Cell proliferation assay: 
ECFC were seeded at a density of 10
3
 cells per well in 96-well flat-bottom plates and 
incubated in complete culture medium overnight. Cells were then exposed 6 h to EGM-2 
(control), MPNH-NH2 or MPNH-COOH suspensions in EGM-2 at the concentration of 0.25 
mg.mL
-1
. Mediums were then removed and three control wells, as well as three MPNH-
treated wells, were treated as follow: the supernatants were removed, wells were gently 
washed using 300 μL of DPBS, cells were treated with 20 μL of trypsin-EDTA for 5 min at 
37°C before adding 40 μL of 10% trypan blue (v/v) EGM-2, cells were transferred in an 
Eppendorf tube and another 20 μL of EGM-2 was used to rince the wells. Cells were then 
counted on a Malassez cell. This action was repeated over time. 
Magnetophoresis: 
Cellular uptake was quantified by means of magnetophoresis,
[48]
 which consists of measuring 
the velocity of labelled cells in a magnetic field gradient of know cartography (magnetic field 
gradient gradB = 18.5 mT.mm
-1
). The iron mass per cell is calculated from the balance of 
viscous force (6πηRυ, η being the water viscosity, R the cell radius, υ the cell velocity) and the 
magnetic force (M*gradB, M being the cell magnetic moment). Measuring, from video 
analysis, the velocity υ and the radius R of cells migrating toward the magnet, we obtain their 
magnetic moment or, equivalently, their iron mass mFe. In addition to the mean cellular 
magnetic load, this assay allows determining the iron mass distribution in the cell population 
(n > 87 cells for each incubation condition). 
Optical characterization of cells: 
Labelled cells were fixed in Eppendorf tubes containing a low gelling point agarose (BMA 
Products, USA) solution 3% (w/v) at 38°C, and a concentration of 1.5.10
6
 ECFC.mL
-1
. 
Eppendorfs were then illuminated for 5 minutes before signal acquisition. Signal acquisition 
was carried out using a photon-counting system based on a cooled GaAs intensified charge-
coupled device (ICCD) camera (Optima, Biospace, Paris, France). 
Magnetic characterization of cells: 
The agarose gels were also used to perform MRI measurements. MRI was performed with a 
dedicated small-animal 4.7 Tesla MR system (Biospec 47/40 USR Bruker), using a 
quadrature transmit/receive body coil with a 35 mm inner diameter. A 5 mm water reference 
tube was also inserted. The T2 sequence was used with following parameters: TR = 12 s, 100 
TE were done from 9 ms with 9 ms between each, 149 x 85 matrix, 3 slices of 1 mm thickness, 
resolution 235 x 235 μm and FOV = 3.5 x 2 cm. The T1 sequence was used with following 
parameters: TE = 11 s, TR = 10 s / 7 s / 4,5 s / 3 s / 1,5 s / 800 ms / 400 ms / 200 ms / 150 ms 
/ 100 ms / 90 ms, 149 x 85 matrix, 3 slices of 1 mm thickness, resolution 235 x 235 μm and 
FOV = 3.5 x 2 cm. 
Scratch test: 
Cell migration assays were performed by plating 3.10
5
 ECFC on 6-well plates until 
confluence was reached. Then, the cells were treated with 73.5 μg.cm-2 (0.25 mg.mL-1) of each 
MPNH-COOH for 6 h. Wells were rinsed with PBS and three wounds were realized in each 
well using a P200 pipette tip. PBS supernatants were discarded and EGM-2 with 2 or 10 % of 
serum was added. Wounds widths were measured 24 h after they were realized. The cells 
were imaged using a Nikon Diaphot inverted contrast microscope. The width of the wounds 
was quantified using ImageJ. Six width measures were performed on three wounds for each 
condition. 
In vitro tube formation assay: 
These experiments were carried out with cells labelled under the same conditions as for the 
previous experiments (MPNH-COOH, 6 h, 73.5 μg.cm-2 / 0.25 mg.mL-1). At the same time, 48-
well plates were coated with 150 μL of growth factor reduced Matrigel. Polymerization of 
Matrigel was realized at 37°C for 1 h. 4.10
4
 control and labelled ECFC were loaded on 
Matrigel and incubated in EGM-2 for 16 h to allow cellular network structures to fully 
developp. Cell structures were imaged using a Nikon Diaphot inverted contrast microscope, 
and networks were characterized with the online software Wimasis Image Analysis, using the 
Wimtube protocol (www.wimasis.com/en/products/13/WimTube). 
In vivo cell imaging and tracking: 
Animal studies were conducted in agreement with the French guidelines for animal care in 
compliance with procedures approved by the Paris Descartes ethics committee for animal 
research (ref. CEEA34.JS.142.12). Five weeks old female BALB/c mice (Janvier, Le Genest 
St. Isle, France) were anesthetized by oral inhalation of isoflurane. A quantity of 5.10
5
 ECFC 
were labelled with either MPNH0-COOH (control) or MPNH2-COOH under previously 
determined conditions (6 h, 73.5 μg.cm-2 / 0.25 mg.mL-1). These ECFC were dispersed in 100 
μL of a 5% sterile D-PBS solution at a concentration of 5.106 ECFC.mL-1. The suspension of 
labelled ECFC was first excited ex vivo for 5 minutes under an orange LED before injection 
in the peritoneal cavity of mice. Animals were then placed on their back under the photon-
counting device, and the signal acquisitions were performed. A luminescence image was 
realized for ten seconds before applying a magnet against the right side of the mouse. 
Luminescence was then followed for ten minutes, until its distribution stops evolving. Four 
ring neodymium magnets (outer diameter 19.1 mm, inner diameter 9.5 mm, height 6.4 mm, 
strength 75.5 N, Supermagnete, Gottmadingen, Germany) were joined to be applied on the 
side of the mouse. 
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Figures 
Figure 1:  TEM images of non-functionalized MPNH0 (a), MPNH1 (b), MPNH2 (c), MPNH3 
(d). e) Decay curves of MPNHs after 2 min UV (254 nm) or red-LED illumination Persistent 
luminescence intensity is expressed in log10 scale in arbitrary units. f) Synthetic pathway from 
MPNHs-OH to MPNHs-COOH. (adapted from [31]) 
 
 
Figure 2: Cytotoxicity of MPNHs in ECFC. a-d) Percentage of viability after 6 (red and blue 
diamonds) or 24 h (black squares) of incubation with MPNHs-NH2 (red curves) or MPNHs-
COOH (blue curves). All types of MPNH (MPNH0 to MPNH3, as shown on graphs (a) to (d), 
respectively) were tested for concentrations from 31.25 μg.mL-1 (9.19 μg.cm-2) to 1 mg.mL-1 
(294 μg.cm-2). e) Cell proliferation after incubation in the absence (control, blue diamonds) or 
presence of MPNH3-NH2 (red squares) or -COOH (green squares) (incubation time 6 h, 
concentration of 0.25 mg.mL
-1
 / 73.5 μg.cm-2). Growth capacity was not affected by the 
carboxylic coating, as opposed to the amino coating, compared with growth capacity in 
control. 
 
Figure 3: Optical and magnetic characterizations of MPNHs labelled ECFC. a-c) Electron 
micrographs of ECFC after 6 h of incubation with MPNH1-COOH (a), MPNH2-COOH (b) 
and MPNH3-COOH (c) (0.25 mg.mL
-1
 / 73.5 μg.cm-2). Fe (d) and MPNH1,2,3-COOH (e) mean 
load per cell after incubation. Statistical analyses were realized using an Anova test followed 
by a Bonferroni comparison. Bar graphs show mean ± SEM (n = 88, 178 and 109 for MPNH1, 
MPNH2 and MPNH3, respectively). ** and *** correspond to p < 0.01 and 0.001, 
respectively. f) T2* MRI measurements and images of agarose gels with 1.5.10
6
 ECFC.mL
-1
. 
Control tube (CT, sky blue) contains the same concentration of unlabelled ECFC. Bar graph 
show mean ± SD, images of corresponding tubes are shown under the graphics. g) Persistent 
luminescence of previously described agarose gels after 5 min of red-LED illumination (bar 
graph show mean ± SD). 
 
 
 
Figure 4: Assessment of the invasion ability of labelled ECFC. a-j) Images of wounds were 
taken 24 h after their realization, when control wounds have disappeared. k) Evaluation of 
invasion latency between control and labelled ECFC. Statistical analyses were realized using 
an Anova test followed by a Bonferroni comparison. Bar graphs show mean bar graph show 
mean ± SD, * indicates p < 0.05. 
 
 
 
 
Figure 5: Vasculogenesis in vitro with labelled cells on Matrigel. Control (a) and MPNH0,1,2,3-
COOH (respectively b, c, d and e) labelled ECFC were incubated at 37°C in EGM-2 during 
16 h to form vascular tubes. f-g) Properties of the vascular network such as the total number 
of tubes (f) or the mean tube length (g) were assessed with an online software (Wimasis). Bar 
graphs represent mean ± SD. 
 
 
Figure 6: In vivo magnetic vectorisation of labelled ECFC and real-time optical imaging of 
their biodistribution. a) Representation of the in vivo experiment and segmentation of mice 
abdomen to follow the evolution of the luminescence distribution. b-e) Caracteristic evolution 
of persistent luminescence distribution in a mouse after injection of MPNH0-COOH labelled 
ECFC (b, control experiment) or MPNH2-COOH labelled ECFC (c) and corresponding 
graphs (respectively d and e). Statistical analyses were realised between the luminescence 
intensities before and 12 min after magnet apposition using an Anova test followed by a 
Bonferroni comparison. * and *** indicate p < 0.05 and p < 0.001. 
 
 
 
  
 
Tables 
Table 1: DLS measurements giving hydrodynamic diameters and ζ-potentials of MPNHs-NH2 
and MPNHs-COOH. 
 Potentiel ζ      
(mV) 
 Hydrodynamic 
Diameter (nm) / 
Polydispersity index 
Potentiel ζ 
(mV) 
MPNH0-NH2 
MPNH1-NH2 
MPNH2-NH2 
MPNH3-NH2 
36,2 ± 1,9 
38,3 ± 0,9 
46,3 ± 2,4 
35,7 ± 2,7 
MPNH0-COOH 
MPNH1-COOH 
MPNH2-COOH 
MPNH3-COOH 
200 / 0,024 
185 / 0,046 
191 / 0,050 
186 / 0,052 
-44,7 ± 2,1 
-42,2 ± 2,1 
-39,2 ± 2,2 
-40,0 ± 2,6 
 
Supplementary 
Figure S1: Iron mass distribution in MPNHs-COOH labelled ECFC. a) MPNH0-COOH, b) 
MPNH2-COOH, c) MPNH3-COOH. 
  
Figure S2: T1* MRI measurements and images of agarose gels with 1.5.10
6
 ECFC.mL
-1
. 
Control tube (CT, sky blue) contains the same concentration of unlabelled ECFC. Bar graph 
show mean ± SD, images of corresponding tubes are shown under the graphics. 
  
 
Figure S3: Supplementary characterizations of vascular network formed by unlabelled and 
MPNHs-COOH labelled ECFC deposited on Matrigel. 
  
 
